[12] FEHB Plans: Zepbound on 2026 Formulary Kaiser FEHB and PSHB plans confirm Zepbound on 2026 formularies at Tier 3/4 (specialty tier)
Faulder CG, Hirrell PA, Hume R, Strange RC
282 van ElstK.BrouwersJ
Johns Hopkins
Instead, the selected literature was analyzed and synthesized thematically, with studies grouped according to biological pathways (e.g., monoaminergic modulation, neurotrophic signaling, HPA-axis regulation, neuroinflammation, oxidative stress, and mitochondrial function) and level of evidence (preclinical versus clinical)
For example, someone who is experiencing hypoglycemia, or low blood sugar, may feel irritable or anxious